HK1097279A1 - Hpv vaccine comprising peptides from host cell proteins - Google Patents

Hpv vaccine comprising peptides from host cell proteins

Info

Publication number
HK1097279A1
HK1097279A1 HK07104187.8A HK07104187A HK1097279A1 HK 1097279 A1 HK1097279 A1 HK 1097279A1 HK 07104187 A HK07104187 A HK 07104187A HK 1097279 A1 HK1097279 A1 HK 1097279A1
Authority
HK
Hong Kong
Prior art keywords
peptides
hpv
host cell
vaccine
cell proteins
Prior art date
Application number
HK07104187.8A
Other languages
English (en)
Inventor
Stephen Tze Kwung Man
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff filed Critical Univ Cardiff
Publication of HK1097279A1 publication Critical patent/HK1097279A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Magnetic Heads (AREA)
  • Saccharide Compounds (AREA)
  • Liquid Crystal (AREA)
HK07104187.8A 2004-08-05 2007-04-20 Hpv vaccine comprising peptides from host cell proteins HK1097279A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417430.6A GB0417430D0 (en) 2004-08-05 2004-08-05 A novel HPV vaccine comprising peptides from host cell proteins
PCT/GB2005/002962 WO2006013336A1 (en) 2004-08-05 2005-07-27 Hpv vaccine comprising peptides from host cell proteins

Publications (1)

Publication Number Publication Date
HK1097279A1 true HK1097279A1 (en) 2007-06-22

Family

ID=32982559

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07104187.8A HK1097279A1 (en) 2004-08-05 2007-04-20 Hpv vaccine comprising peptides from host cell proteins

Country Status (11)

Country Link
US (2) US7538183B2 (de)
EP (1) EP1773876B1 (de)
JP (1) JP2008508873A (de)
CN (1) CN101027317B (de)
AT (1) ATE457030T1 (de)
AU (1) AU2005268646B2 (de)
CA (1) CA2575610C (de)
DE (1) DE602005019238D1 (de)
GB (1) GB0417430D0 (de)
HK (1) HK1097279A1 (de)
WO (1) WO2006013336A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI441648B (zh) 2007-01-03 2014-06-21 Oncotherapy Science Inc Ｆｏｘｐ３胜肽疫苗
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CN102234688A (zh) * 2010-04-30 2011-11-09 北京心意圆成生物科技有限公司 一种哺乳动物细胞dna快速定量检测方法
US20150087810A1 (en) 2013-09-25 2015-03-26 Cytomx Therapeutics, Inc. Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
DK3628328T3 (da) 2014-01-31 2022-12-05 Cytomx Therapeutics Inc Matriptase- og u-plasminogen-aktivatorsubstrater og andre spaltelige dele og fremgangsmåder til anvendelse deraf
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
US10238729B2 (en) 2014-10-24 2019-03-26 Hpvvax, Llc Cancer and skin lesion treatment
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
US10702598B2 (en) 2016-06-20 2020-07-07 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
MX2019003961A (es) * 2016-10-05 2019-08-26 Pds Biotechnology Corp Vacunas novedosas del vph16 con celulas t no restringidas por hla, composiciones y metodos de uso de las mismas.
WO2022091531A1 (ja) * 2020-10-28 2022-05-05 国立大学法人北海道大学 抗腫瘍ペプチド及びその利用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183746B1 (en) * 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
DE19859486A1 (de) * 1998-12-22 2000-07-06 Razvan Tudor Radulescu Peptide mit besonderen antiproliferativen Eigenschaften
US6440696B1 (en) * 1999-07-28 2002-08-27 New England Medical Center E6 targeted protein (E6TP1)
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
FR2839072A1 (fr) * 2002-04-24 2003-10-31 Neovacs Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation
WO2004013631A2 (en) * 2002-07-29 2004-02-12 Mtm Laboratories Ag Compositions and methods for diagnosis and therapy of cancer
KR101145190B1 (ko) * 2002-10-03 2012-05-14 와이어쓰 홀딩스 코포레이션 사람 파필로마바이러스 폴리펩타이드 및 면역원성 조성물

Also Published As

Publication number Publication date
EP1773876A1 (de) 2007-04-18
US7538183B2 (en) 2009-05-26
AU2005268646A2 (en) 2006-02-09
WO2006013336A9 (en) 2007-03-29
CA2575610C (en) 2014-02-11
CN101027317A (zh) 2007-08-29
CN101027317B (zh) 2013-01-30
EP1773876B1 (de) 2010-02-03
GB0417430D0 (en) 2004-09-08
JP2008508873A (ja) 2008-03-27
US20090232842A1 (en) 2009-09-17
ATE457030T1 (de) 2010-02-15
WO2006013336A1 (en) 2006-02-09
DE602005019238D1 (de) 2010-03-25
US20070218074A1 (en) 2007-09-20
AU2005268646B2 (en) 2011-01-06
AU2005268646A1 (en) 2006-02-09
CA2575610A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
HK1097279A1 (en) Hpv vaccine comprising peptides from host cell proteins
NO2018010I1 (no) HPV 31 L1 protein
EP3584251A3 (de) Hpv-epitope als ziel für zervikale tumoren infiltrierende t-zellen zur verwendung bei impfstoffen
WO2010149752A3 (en) Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
AR077396A2 (es) EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS
Lee et al. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects
WO2007039192A3 (en) Compositions and methods for treating tumors presenting survivin antigens
WO2003000928A3 (en) Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
MX2011007307A (es) Vector de expresion estable contitutivamente alto para preparar vacuna vph y bacteria acido lactica recombinante transformada del mismo modo.
NZ597182A (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
MX2017005788A (es) Vacunas terapeuticas contra el vph16.
WO2005047315A3 (en) Optimized expression of hpv 58 l1 in yeast
WO2006081826A3 (en) Survivin peptide vaccine
WO2004044176A8 (en) Adenoviral vector vaccine
EP2589604A4 (de) Verkürztes l1-protein des humanen papillomavirus vom typ 52
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
Venuti et al. An E7-based therapeutic vaccine protects mice against HPV16 associated cancer
AR108781A1 (es) Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv)
NZ594198A (en) Neil3 peptides and vaccines including the same
AU2001259217A1 (en) Human pellino polypeptides
WO2004053092A3 (en) Human pellino polypeptides
Liu et al. Immunotherapy of Epstein-Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356–364 epitope fusion protein
SI1537204T1 (sl) Granzim b kot povzročitelj apoptoze odvisen od peptida Hsp Hsp v tumorskih celicah
UA98254C2 (ru) мукозальная вакцина для иммунотерапии заболеваний, обусловленных вирусами папилломы человека
Bolhassani et al. Enhancement of potent immune responses to HPV16 E7 antigen by using different vaccine modalities